CROI 2016 Program at a Glance

Program and Agenda

Ballroom B/C

Session S-4 Symposium 4:00 PM-6:00 PM Innovations in PrEP

Auditorium

Session S-3 Symposium

CME

CME

4:00 PM-6:00 PM Global Impact of Hepatitis

Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy. Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment. Objectives: At the completion of the session, participants will be able to: • Compare the global burden and epidemiology of hepatitis B and C • Describe Egypt as a model for hepatitis C transmission around the world and the approaches to disease eradication • Identify the mechanism of antiviral activity of hepatitis C medications including those effective against all genotypes • Compare immunologic and virologic mechanisms for eradication of hepatitis B Conveners

Target audience: This session is directed to clinicians and scientists who are interested in understanding antiretroviral preexposure prophylaxis (PrEP) for HIV prevention. Level of knowledge: It is assumed that participants are familiar with basic concepts of how PrEP is used for HIV prevention. Objectives: At the completion of the session, participants will be able to: • Describe the current experience in PrEP delivery models • Describe the potential increases in sexually transmitted infections associated with PrEP programs • Describe approaches to promoting the use of PrEP • List the potential advantages and disadvantages of current and future potential PrEP modalities • Describe opportunities for other prevention modalities in light of low uptake of PrEP in some populations Conveners Albert Y. Liu ,SanFranciscoDepartmentof

PublicHealth,SanFrancisco,CA,USA Dawn K. Smith ,Centers forDisease ControlandPrevention,Atlanta,Georgia, USA 4:00 68 Delivery of PrEP: From Evidence to Practice C. Bradley Hare ,KaiserPermanente NorthernCalifornia,SanFrancisco,CA,USA 4:30 69 Sexually Transmitted Infection Control in the Era of PrEP Sheena McCormack ,UnivCollLondon, London,UK 5:00 70 PrEP-4-Love: Transmitting Desire Across Chicago James Pickett ,AIDSFndnofChicago, Chicago, IL,USA 5:30 71 The Promise and Challenges of Sustained Delivery of PrEP Ian McGowan ,UnivofPittsburghSchof Med,Pittsburgh,PA,USA

Gottfried Hirnschall ,WorldHealth Organization,Geneva,Switzerland Andri Rauch ,BernUniversityHospitaland UniversityofBern,Bern,Switzerland 4:00 64 Hepatitis C: Global Epidemiology ImamWaked ,NatlLiver Inst,ShebeenEl Kom,Egypt

Oral Sessions • Tuesday, February 23, 2016

4:30 65 Refer to the CROI Mobile App

and the CROI website for updates on this presentation

5:00 66 Hepatitis C Therapeutics:

Pangenotypic Therapeutics on the Horizon Karine LaCombe ,SorbonneUnivs,Paris, France

5:30 67 Hepatitis B Virus: Is a Cure Possible?

Chloe Thio , JohnsHopkinsUniv,Baltimore, MD,USA

32

CROI 2016